The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
A Leicester doctor tried Mounjaro for obesity and was shocked by how it silenced his 'food noise' and curbed alcohol desires, alongside significant weight loss. But stopping brought cravings back fast. Discover his message on long-term use, side effects, and who should consider it.
A superintendent pharmacist is urging Mounjaro users to take specific precautions when traveling on holiday, from buffet strategies to proper medication storage. Buffets pose unique challenges for GLP-1 users, and extreme temperatures in plane cargo holds can ruin pens. Get expert advice to keep your weight loss journey on track.
On The View, Joy Behar opened up about her GLP-1 weight loss success, noting she was prediabetic before starting. Co-host Sunny Hostin shared gaining 40 lbs during COVID and using Mounjaro to improve her cholesterol from 200 to 140. These stories highlight Hollywood's trend toward Ozempic and similar drugs for real health gains.
Peptides are everywhere on TikTok, with gym bros claiming stacks like Ipamorelin and CJC1295 supercharge muscle growth and recovery. But do these injectable amino acid chains really deliver, or is it hype? Experts weigh in on the science, safety, and why caution is key amid a $81.5 billion industry boom.
Emerging evidence suggests GLP-1 receptor agonists (GLP-1 RAs) not only aid weight loss but also significantly quiet 'food noise'—those persistent, distressing thoughts about food. In the US-based INFORM survey, 550 individuals using GLP-1s reported a 46% reduction in constant food thoughts, alongside mental health gains. This could redefine obesity management for better holistic outcomes.
Gonadorelin 5mg research peptide is gaining traction in studies of hormonal health and reproductive medicine. This synthetic GnRH mimic helps researchers investigate gonadotropin release, hormonal imbalances, and therapies for conditions like hypogonadism. Delve into its mechanisms, efficacy metrics, and essential ethical considerations for robust clinical research.
New research reveals a stark 'Mounjaro gap' in weight-loss drug access, with middle-class women far more likely to use GLP-1 jabs like Mounjaro privately, deepening class divides. Patients like Kelly Todd face years-long NHS waits despite eligibility. Experts warn this entrenches health inequalities amid high private costs of £144-£324 monthly.
Global food giants like PepsiCo and Coca-Cola are ramping up investments in rebranded, protein-rich products as GLP-1 drugs suppress appetite and alter eating habits across 20% of U.S. households. With potential $12 billion in lost snack sales over the next decade, companies are shifting to smaller portions and nutrient-dense options. This adaptation highlights the lasting ripple effects of obesity medications on the food industry.
